EBOS prepped for life after CWH

Pharmaceutical wholesaler reports strong growth ahead of Chemist Warehouse’s switch to rival  Symbion’s parent company, EBOS Group is reporting “strong normalised growth” for the first half of the 2023/24 financial year, excluding its Chemist Warehouse (CWH) business.  Releasing its half-year results, EBOS noted that its healthcare business had reported its underlying EBITDA (earnings before interest, taxes,